Literature DB >> 17554628

Interest in breast cancer chemoprevention among older women.

Jennifer Tjia1, Ellyn Micco, Katrina Armstrong.   

Abstract

OBJECTIVES: The study aim is to describe interest in breast cancer chemoprevention among older women without a history of breast cancer and to determine whether aging-related factors such as diminished life expectancy, increasing comorbidity and medication burden attenuate chemoprevention interest.
DESIGN: Cross-sectional survey.
SETTING: University of Pennsylvania Health System. PARTICIPANTS: Four-hundred fifty-seven community-dwelling women aged 60-65 years old who were potentially eligible for breast cancer chemoprevention according to guidelines linking risk and eligibility to age. MEASUREMENTS: Interest in breast cancer chemoprevention, Gail model breast cancer risk, perceived breast cancer risk, breast cancer worry, self-reported health status and comorbidities, and self-reported perceived life expectancy.
RESULTS: Of 457 participants, 11.2% reported being interested in taking chemoprevention, 40.9% reported no interest, and 47.9% reported being unsure about their interest in chemoprevention. Overall, interest in chemoprevention was not associated with individual Gail model breast cancer risk. In adjusted analysis, lack of interest among high-risk women was associated with low breast cancer worry and low perceived risk. Conversely, interest in chemoprevention among low risk women was associated with greater breast cancer worry. Age-related factors hypothesized to affect chemoprevention interest, including subjective life expectancy, increased comorbidity, and number of daily medications did not attenuate chemoprevention interest.
CONCLUSION: Breast cancer worry and perceived breast cancer risk contribute to the lack of correlation between interest in breast cancer chemoprevention and objective breast cancer risk. Perceived life expectancy, increased comorbidity, and medication burden do not attenuate chemoprevention interest among older women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554628     DOI: 10.1007/s10549-007-9614-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

Review 1.  Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.

Authors:  Mary E Ropka; Jess Keim; John T Philbrick
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Risk-benefit profiles of women using tamoxifen for chemoprevention.

Authors:  Hazel B Nichols; Lisa A DeRoo; Daniel R Scharf; Dale P Sandler
Journal:  J Natl Cancer Inst       Date:  2014-12-03       Impact factor: 13.506

Review 3.  Burden of treatment for chronic illness: a concept analysis and review of the literature.

Authors:  Adem Sav; Michelle A King; Jennifer A Whitty; Elizabeth Kendall; Sara S McMillan; Fiona Kelly; Beth Hunter; Amanda J Wheeler
Journal:  Health Expect       Date:  2013-01-31       Impact factor: 3.377

Review 4.  Raloxifene: a review of its use in the prevention of invasive breast cancer.

Authors:  Marit D Moen; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  A case-control study on risk factors of breast cancer in China.

Authors:  Ya-Li Xu; Qiang Sun; Guang-Liang Shan; Jin Zhang; Hai-Bo Liao; Shi-Yong Li; Jun Jiang; Zhi-Min Shao; Hong-Chuan Jiang; Nian-Chun Shen; Yue Shi; Cheng-Ze Yu; Bao-Ning Zhang; Yan-Hua Chen; Xue-Ning Duan; Bo Li
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

Review 6.  Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.

Authors:  B Meiser; W K T Wong; M Peate; C Julian-Reynier; J Kirk; G Mitchell
Journal:  Hered Cancer Clin Pract       Date:  2017-09-20       Impact factor: 2.857

7.  A case-control study on risk factors of breast cancer in Han Chinese women.

Authors:  Li-Yuan Liu; Fei Wang; Shu-De Cui; Fu-Guo Tian; Zhi-Min Fan; Cui-Zhi Geng; Xu-Chen Cao; Zhen-Lin Yang; Xiang Wang; Hong Liang; Shu Wang; Hong-Chuan Jiang; Xue-Ning Duan; Hai-Bo Wang; Guo-Lou Li; Qi-Tang Wang; Jian-Guo Zhang; Feng Jin; Jin-Hai Tang; Liang Li; Shi-Guang Zhu; Wen-Shu Zuo; Li-Xiang Yu; Yu-Juan Xiang; Fei Zhou; Liang Li; Qiang Zhang; Qin-Ye Fu; Zhong-Bing Ma; De-Zong Gao; Yu-Yang Li; Lu Liu; Chun-Miao Ye; Yong-Jiu Wang; Wen-Zhong Zhou; Zhi-Gang Yu
Journal:  Oncotarget       Date:  2017-10-09

8.  Women's decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals.

Authors:  Linda Rainey; Daniëlle van der Waal; Louise S Donnelly; D Gareth Evans; Yvonne Wengström; Mireille Broeders
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

9.  Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.

Authors:  Kelly E Lloyd; Louise H Hall; Lucy Ziegler; Samuel G Smith
Journal:  Breast Cancer Res Treat       Date:  2021-03-17       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.